Thrombophilia differences in cerebral venous sinus and lower extremity deep venous thrombosis

Neurology

Volumn 70, Issue 8, 2008, Pages 627-633

  Wysokinska, E M ^a,b   Wysokinski, W E ^a   Brown, R D ^a   Karnicki, K ^a   Gosk Beirska, I ^b   Grill, D ^a   McBane II, R D ^a  

^a MAYO CLINIC   (United States)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN M; PROTEIN C; PROTHROMBIN;

ACTIVATED PROTEIN C RESISTANCE; ADULT; ARTICLE; CEREBRAL VENOUS SINUS THROMBOSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CONVENTIONAL ANGIOGRAPHY; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; FEMALE; GENE MUTATION; HETEROZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; PROTEIN C DEFICIENCY; THROMBOPHILIA;

EID: 39749144548     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000297195.97325.a8     Document Type: Article

References (37)

1. Stam J. Thrombosis of the cerebral veins and sinuses. N Engl J Med 2005;352:1791-1798.
2. Ferro JM, Canhao P, Stam J, Bousser MG, Barinagarrementeria F. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke 2004;35:664-670.
3. Gosk-Bierska I, Wysokinski W, Brown RD Jr, et al. Cerebral venous sinus thrombosis: incidence of venous thrombosis recurrence and survival. Neurology 2006;67:814-819.
4. Kimber J. Cerebral venous sinus thrombosis. QJM 2002;95:137-142.
5. Martinelli I, Landi G, Merati G, Cella R, Tosetto A, Manucci PM. Factor V gene mutation is a risk factor for cerebral venous thrombosis. Thromb Haemost 1996;75:393-394.
6. Brey RL, Coull BM. Cerebral Venous Thrombosis: Role of activated protein C resistance and factor V gene mutation. Stroke 1996;27:1719-1720.
7. Zuber M, Toulon P, Mas LMJ. Factor V Leiden mutation in cerebral venous thrombosis Stroke 1996;27:1721-1723.
8. Dulli DA, Luzzio CC, Williams EC, Schutta HS. Cerebral venous thrombosis and activated protein C resistance. Stroke 1996;27:1731-1733.
9. Deschiens MA, Conard J, Horellou MH, et al. Coagulation studies, factor V Leiden, and anticardiolipin antibodies in 40 cases of cerebral venous thrombosis. Stroke 1996;27:1724-1730.
10. Carhuapoma JR, Mitsias P, Levine SR. Cerebral venous thrombosis and anticardiolipin antibodies. Stroke 1997;28:2363-2369.
11. Reuner KH, Ruf A, Grau A, et al. Prothrombin Gene G20210A transition is a risk factor for cerebral venous thrombosis. Stroke 1998;29:1765-1769.
12. de Bruijn SF, Stam J, Koopman MM, Vandenbroucke JP. Case-control study of risk of cerebral sinus thrombosis in oral contraceptive users who are carriers of hereditary prothrombotic conditions. BMJ 1998;316:589-592.
13. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Manucci PM. High risk of cerebral-vein thrombosis in carriers of prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998;338:1793-1797.
14. Cakmak S, Derex L, Berruyer M, et al. Cerebral venous thrombosis: clinical outcome and systematic screening of prothrombotic factors. Neurology 2003;60:1175-1178.
15. Martinelli I, Battaglioli T, Pedptti P, Cattaneo M, Manucci PM. Hyperhomocysteinemia in cerebral vein thrombosis. Blood 2003;102:1363-1366.
16. Francis RB, Seyfert U. Rapid amidolytic assay for protein C in whole plasma using an activator from the venom of agkistrodon contortrix. Am J Clin Pathol 1987;87:619-625.
17. Laroche P, Plassart V, Amiral J. "Rapid quantitative latex immunoassays for diagnosis of thrombotic disorders." Thromb Haemost 1989;62:379.
18. Zöller B, García de Frutos P, Dahlbäck B. Evaluation of the relation between protein S and C4b-binding protein isoforms in hereditary protein S deficiency demonstrating type I and type III deficiencies to be phenotypic variants of the same genetic disease. Blood 1995;85:3524-3531.
19. Tollefsen DM. Laboratory diagnosis of antithrombin and heparin cofactor II deficiency. Sem Thromb Haemost 1990;16:162-168.
20. Kapiotis S, Quehenberger P, Jilma B, et al. Improved characteristics of APC resistance assay, Coatest aPC resistance by predilution of samples with Factor V deficient plasma. Am J Clin Pathol 1996;106:588-593.
21. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:64-67.
22. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996;88:3698-3703.
23. Heit JA, Meyers BJ, Plumhoff EA, Larson DR, Nichols WL. Operating characteristics of automated plasma fibrin D-dimer assays in the diagnosis of angiographically defined acute pulmonary embolism. Thromb Haemost 2000;83:970.
24. Magera MJ, Lacey JM, Casetta B, Rinaldo P. Method for the determination of total homocysteine in plasma and urine by stable isotope dilution and electrospray tandem mass spectrometry. Clin Chem 1999;45:1517-1522.
25. SAS Institute Inc. SAS/STAT User's Guide, Version 9 edition. Cary, NC: SAS Institute Inc., 2005.
26. Tanne D, D'Olhaberriague L, Trivedi AM, Salowich-Palm L, Schultz LR, Levine SR. Anticardiolipin antibodies and mortality in patients with ischemic stroke: a prospective follow-up study. Neuroepidemiology 2002;21:93-99.
27. Wu O, Robertson L, Langhorne P, et al. Oral contraceptives, hormone replacement therapy, thrombophilias and risk of venous thromboembolism: a systematic review. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Thrombosis Haemostasis 2005;94:17-25.
28. Venous thromboembolic disease and combined oral contraceptives: results of international multi centre case-control study: World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Lancet 1995;346:1575-1582.
29. Kitty W, Bloemenkamp M, Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Higher risk of venous thrombosis during early use of oral contraceptives in women with inherited clotting defects. Arch Intern Med 2000;160:49-52.
30. Koenen RR, Christella M, Thomassen LG, Tans G, Rosing J, Hackeng TM. Effect of oral contraceptives on the anticoagulant activity of protein S in plasma. Thromb Haemost 2005;93:853-859.
31. Kluft C, Lansink M. Effect of oral contraceptives on haemostasis variables. Thromb Haemost 1997;78:315-326.
32. Legnani C, Cosmi B, Valdre L, et al. Venous thromboembolism, oral contraceptives and high prothrombin levels. J Thromb Haemost 2003;1:112-117.
33. Tsai LK, Jeng JS, Liu HM, Wang HJ, Yip PK. Intracranial dural arteriovenous fistulas with or without cerebral sinus thrombosis: analysis of 69 patients. J Neurol Neurosurg Psychiatry 2004;75:1639-1641.
34. Gerlach R, Yahya H, Rohde S, et al. Increased incidence of thrombophilic abnormalities in patients with cranial dural arteriovenous fistulae. Neurol Res 2003;25:745-748.
35. McBane RD 2nd, Miller RS, Hassinger NL, Chesebro JH, Nemerson Y, Owen WG. Tissue prothrombin. Universal distribution in smooth muscle. Arterioscler Thromb Vasc Biol 1997;17:2430-2436.
36. Dihanich M, Kaser M, Reinhard E, Cunningham D, Monard D. Prothrombin mRNA is expressed by cells of the nervous system. Neuron 1991;6:575-581.
37. Weinstein JR, Gold SJ, Cunningham D, Gall CM. Cellular localization of thrombin receptor mRNA in rat brain: expression by mesencephalic dopaminergic neurons and codistribution with prothrombin mRNA. J Neurosci 1995;15:2906-2919.